Rationale for a Combination Therapy with the STAT5 Inhibitor AC-4-130 and the MCL1 Inhibitor S63845 in the Treatment of FLT3-Mutated or TET2-Mutated Acute Myeloid Leukemia.
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Cell Line, Tumor
DNA-Binding Proteins
/ genetics
Dioxygenases
Humans
Leukemia, Myeloid, Acute
/ drug therapy
Proto-Oncogene Proteins
/ genetics
Pyrimidines
/ therapeutic use
STAT5 Transcription Factor
/ antagonists & inhibitors
Thiophenes
/ therapeutic use
Tumor Suppressor Proteins
/ antagonists & inhibitors
fms-Like Tyrosine Kinase 3
/ genetics
FMS-like tyrosine kinase 3 (FLT3)
acute myeloid leukemia (AML)
hematological malignancies
myeloid leukemia cell differentiation protein (MCL1)
signal transducer and activator of transcription 5 (STAT5)
ten-eleven translocation-2 (TET2)
tumor suppressor p53 (TP53)
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
28 Jul 2021
28 Jul 2021
Historique:
received:
28
05
2021
revised:
19
07
2021
accepted:
26
07
2021
entrez:
7
8
2021
pubmed:
8
8
2021
medline:
15
9
2021
Statut:
epublish
Résumé
The FMS-like tyrosine kinase 3 (
Identifiants
pubmed: 34360855
pii: ijms22158092
doi: 10.3390/ijms22158092
pmc: PMC8347059
pii:
doi:
Substances chimiques
DNA-Binding Proteins
0
Proto-Oncogene Proteins
0
Pyrimidines
0
S63845
0
STAT5 Transcription Factor
0
STAT5A protein, human
0
Thiophenes
0
Tumor Suppressor Proteins
0
Dioxygenases
EC 1.13.11.-
TET2 protein, human
EC 1.13.11.-
FLT3 protein, human
EC 2.7.10.1
fms-Like Tyrosine Kinase 3
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
ID : #310030_127509
Références
Int J Mol Sci. 2020 Feb 24;21(4):
pubmed: 32102366
Immunity. 2015 Aug 18;43(2):251-63
pubmed: 26275994
Genes Cancer. 2010 Oct;1(10):979-93
pubmed: 21442038
Leukemia. 2014 Mar;28(3):485-96
pubmed: 24220273
Leukemia. 2018 Aug;32(8):1713-1726
pubmed: 29728695
Blood. 2009 Dec 3;114(24):5034-43
pubmed: 19808698
Haematologica. 2019 Oct;104(10):2017-2027
pubmed: 30923103
Haematologica. 2019 Oct;104(10):1907-1909
pubmed: 31575669
Leukemia. 2018 May;32(5):1135-1146
pubmed: 29472718
J Leukoc Biol. 2015 Feb;97(2):279-83
pubmed: 25492937
Cancers (Basel). 2019 Nov 12;11(11):
pubmed: 31718075
Mol Cell. 2015 Feb 19;57(4):662-673
pubmed: 25601757
JAKSTAT. 2012 Jan 1;1(1):13-22
pubmed: 24058747
Cancers (Basel). 2018 May 31;10(6):
pubmed: 29857559
J Immunol Res. 2018 Jun 14;2018:6985031
pubmed: 30013992
Leukemia. 2003 Jul;17(7):1263-93
pubmed: 12835716
Cancers (Basel). 2021 Mar 24;13(7):
pubmed: 33805247
Cytometry A. 2018 Jul;93(9):929-940
pubmed: 30247803
Cancer Cell. 2010 Dec 14;18(6):553-67
pubmed: 21130701
Cancers (Basel). 2021 Feb 02;13(3):
pubmed: 33540760
Ann Transl Med. 2020 Nov;8(21):1346
pubmed: 33313091
Leukemia. 2014 Nov;28(11):2257-60
pubmed: 25030047
PLoS One. 2009 Nov 24;4(11):e7989
pubmed: 19956772
Cancer Res. 2010 Jan 15;70(2):440-6
pubmed: 20068163
Toxicol Appl Pharmacol. 2018 Nov 1;358:43-55
pubmed: 30213730
Blood Rev. 2018 Nov;32(6):508-519
pubmed: 29728319
Apoptosis. 2004 Nov;9(6):717-28
pubmed: 15505414
J Hematol Oncol. 2011 Apr 01;4:13
pubmed: 21453545
Haematologica. 2018 Nov;103(11):1862-1872
pubmed: 29976747
Clin Cancer Res. 2003 Jun;9(6):2140-50
pubmed: 12796379
Oncol Res. 2016;24(4):215-23
pubmed: 27656831
Leukemia. 2016 Mar;30(3):666-73
pubmed: 26514544
Oncotarget. 2016 Jun 14;7(24):36266-36279
pubmed: 27167113
Cancers (Basel). 2020 Jan 18;12(1):
pubmed: 31963765